Trends in Pharmacy Compounding for Women’s Health in North Carolina: a Focus on Vulvodynia by Iyer, Priya et al.
The Safe Drug Compounding Act of 2007 threatens to adversely affect 
many patients who rely on compounded medications to treat medical 
conditions for which no adequate commercially manufactured 
medication is available. Currently, no standard treatment for 
vulvodynia exists and many women rely on compounded medications 
to control the symptoms of this complex condition. In order to better 
understand the importance of compounding pharmacies in the 
provision of women’s health services and to identify trends in 
compounding for vulvodynia, we developed an online survey with the 
assistance of the University of North Carolina’s Odum Institute. The 
survey was distributed to compounding pharmacies across North 
Carolina.                                                                                                     
Our a priori hypothesis was that many areas of women’s health, 
specifically vulvo-vaginal disorders, rely heavily on compounding 
pharmacies and the services they provide.  
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To establish the prevalence of medications compounded for women’s 
health issues across North Carolina. To identify trends in compounding 
for vulvodynia, with particular emphasis on the types and 
combinations of medications used.    
Compounding pharmacies play a critical role in compounding medications that are not commercially available for 
disorders without consensus treatment, such as vulvodynia. Women’s health issues are the third leading reason for 
compounding medications, with 13.09% (n = 25) of pharmacies compounding medications for vulvar pain.  
BACKGROUND 
The study began July 1, 2007 and concluded December 31, 2007. A list 
of registered pharmacies in North Carolina was obtained from the 
North Carolina Board of Pharmacy. Since the study focused on 
compounding pharmacies we initially excluded 1020 chain pharmacies. 
The remaining 1284 pharmacies were contacted via telephone to 
determine eligibility. Pharmacies that stated they compound 
medications were sent an invitation to complete an online survey, which 
consisted of demographic-type questions as well as questions designed 
to gain information regarding medications compounded for women’s 
health, and more specifically, vulvodynia.   
Fig. 1: Percentage of pharmacies compounding medications for women’s health issues. 
• 1157 pharmacies in North Carolina stated they 
compound medications, thus meeting the inclusion 
criteria for study participation. Of these, 16.5%          
(n = 191) completed the survey. 
•45% (n = 86) of pharmacies compound medications 
for women’s health issues, ranking third behind ENT 
(81%) and dermatology (71%).  
•13.09% (n = 25) of pharmacies compound 
medications for vulvar pain. 
•Medications for vaginal dryness were compounded 
by 31.41% (n = 60) of pharmacies.  
• The most common reason cited by pharmacies 
(43.98%, n = 84) for compounding medications was 
the “combination of medications not commercially 
available.” 
• Strengths of estradiol used in compounding 
preparations varied from 0.005% to 0.06%, with 
0.01% being the most common strength (5.8%,    
n = 11). 
•The most common medication used for vulvar 
pain was lidocaine (7.9%, n=15), followed by 
estradiol, estriol, and testosterone (6.8%, n=13). 
• The most common base used for compounding 
was emollient cream (5.2%, n = 10), followed by 
petrolatum (4.7%, n = 9) and acid mantle (4.2%, 
n = 8)  Fig. 2 : Strengths of estradiol commonly used in compounding medications for vulvodynia 
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